Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

Tools to help you put the guidance into practice.

Anhydrous sodium thiosulfate (Pedmarqsi, Norgine) is indicated for 'the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, ...

NICE is unable to make a recommendation about the use in the NHS of niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is ...

Anhydrous sodium thiosulfate (Pedmarqsi) is available on the NHS. It is a possible treatment for preventing hearing loss caused by cisplatin chemotherapy. It is suitable for babies, children and young ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...